Kiniksa Pharmaceuticals International (KNSA) reported Q1 net income Tuesday of $0.11 per diluted share, swinging from a loss of $0.25 a year earlier.

Analysts polled by FactSet expected $0.13.

Revenue for the quarter ended March 31 was $137.8 million, up from $79.9 million a year earlier.

Analysts surveyed by FactSet expected $131.9 million.

For 2025, the life sciences company lifted its net product revenue expectation to a range of $590 million to $605 million, from between $560 million and $580 million.

Shares of the company were up 4.8% in recent premarket activity.